WHO Reported 180 Million River Blindness Treatments
In 2025, the World Health Organization confirmed that 70.5% of people requiring care for river blindness received treatment.
Updated on Oct. 12, 2026 in Diseases — General
Live Poll
Do you trust international health organizations to maintain consistent disease prevention services for underserved global populations?
The World Health Organization reported that 180.3 million people received treatment for river blindness in 2025. This effort left 75.4 million individuals who required but did not receive necessary care for the parasitic disease.
Why it matters
The parasitic disease, caused by Onchocerca volvulus, remains a significant health challenge as funding gaps and safety concerns continue to hinder mass drug administration efforts in various regions. Successful treatment programs are essential to moving affected populations toward the goal of post-treatment surveillance.
Global treatment coverage reached 70.5% in 2025, while 38 million people resided in areas that completed or were undergoing post-treatment surveillance. Nigeria accounted for 28 million of those individuals currently in surveillance programs.
The players
World Health Organization
This specialized agency of the United Nations is responsible for international public health and tracking progress toward the eradication of neglected tropical diseases.
The details
The disease is managed through the mass administration of ivermectin to interrupt transmission. While some areas have progressed to post-treatment surveillance, other regions such as Angola, Gabon, and Sudan did not implement mass treatment programs throughout 2025.
Timeline
The global treatment data covers the full calendar year of 2025.
The World Health Organization published its official progress report on October 9, 2026.
Health Landscape
The current treatment coverage rates reflect progress toward the World Health Organization's 2030 road map for neglected tropical diseases. This reporting updates figures previously established by the targets set in the program.
The data highlights that effective public health intervention remains uneven, with specific regions facing significant barriers to routine ivermectin access. These service interruptions, such as those in Cameroon due to funding issues, demonstrate how geopolitical and financial stability directly dictate the availability of essential care for residents.
The takeaway
Reliable access to medication is the primary driver of disease elimination in regions affected by river blindness. Ensuring consistent international funding and addressing co-infection safety risks are critical to closing the gap for the 75.4 million people still in need of treatment.
Further reading
For more on the status of global health initiatives, visit the Diseases — General section.
Source note: This article includes information reported by PakTribune.
Live Poll
Do you trust international health organizations to maintain consistent disease prevention services for underserved global populations?
